Is Lexaria Bioscience going out of business?

LEXARIA BIOSCIENCE CORP. (LEXX) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

LEXARIA BIOSCIENCE CORP. (LEXX) scores 26 out of 100 on fundamentals, Distressed / Caution, based on SEC filing data.

Leading signal: ROIC: -584.28%

Five questions, kept separate

Survival - Critical

3-5 mo of estimated runway from 2026-05-31, based on $3.6M of cash and short-term investments against $11.6M of annual burn. Adjusted shares outstanding increased 34.7% over the comparison year.

Business quality - Pre-commercial

Operating margins cannot grade a pipeline; Survival and clinical evidence remain the relevant lenses here.

Trajectory - Clinical progress unavailable

Fundamentals can show funding and burn, but not whether the clinical pipeline is advancing.

Valuation - Balanced

31.8% net-cash backing support a balanced pre-commercial Valuation assessment.

Event risk - Evidence unavailable

No active asserted adverse event was found in the available filing evidence. The filing evidence is stale or incomplete, so this is not proof of absence.

What the rules read

• Debt / Equity: -0.75x (Net Cash)
• ROIC: -584.28%
• Cash Runway (years): 0.31y
• Revenue CAGR (3Y): 40.34%
• Shares dilution YoY: 34.74% (YoY)
• Return on Assets: -161.74%
• FCF margin: -5999.58% (Inv. Mode)
• Price / Sales: 57.6x (see Valuation)
• Price / Earnings: Unprofitable (see Valuation)

Read from filings through 2026-07-13.

Price as of 2026-09-07.